Hydrocortisone May Lower Severe CAP Mortality - Summary - MDSpire

Hydrocortisone May Lower Severe CAP Mortality

Network meta-analysis suggests hydrocortisone may offer mortality and ventilation benefits, although evidence certainty remained low.

  • By

  • Andrea Surnit

  • May 11, 2026

  • 3 min

Share

Objective:

To evaluate the impact of different corticosteroids on mortality in patients with severe community-acquired pneumonia (CAP).

Key Findings:
  • Hydrocortisone was associated with a relative reduction of approximately 65% in all-cause mortality risk compared to placebo.
Interpretation:

Hydrocortisone may be more effective than other corticosteroids in reducing mortality and mechanical ventilation needs in severe CAP, but findings are based on indirect comparisons and should be interpreted with caution.

Limitations:
  • Reliance on indirect comparisons due to all studies comparing corticosteroids with placebo.
  • Low certainty of evidence due to imprecision, heterogeneity, and variability in study designs, including definitions of severe CAP and corticosteroid dosing strategies.
  • Limited statistical power for subgroup analyses.
Conclusion:

While hydrocortisone shows promise in reducing mortality in severe CAP, the evidence is not robust enough to change current treatment guidelines, and further research is needed.

Original Source(s)

Hydrocortisone May Lower Severe CAP Mortality

  • by Andrea Surnit

  • May 11, 2026

Related Content

Hemodynamic Instability in Intubation May Be Predictable

Narrative review describes how physiologic stressors accumulate from induction through postintubation care and may contribute to cardiovascular deterioration during airway management.

Ensitrelvir Reduced COVID After Household Exposure

In SCORPIO-PEP, symptomatic COVID-19 occurred in 3% vs 9% of household contacts by day 10.

Medical Oddities: Something Viral is Lurking in the Dust

Everyday things like yawns, tea, dust, and kimchi suddenly look medically important.